NZ748173A - Macrocyclic mcl1 inhibitors for treating cancer - Google Patents

Macrocyclic mcl1 inhibitors for treating cancer

Info

Publication number
NZ748173A
NZ748173A NZ748173A NZ74817317A NZ748173A NZ 748173 A NZ748173 A NZ 748173A NZ 748173 A NZ748173 A NZ 748173A NZ 74817317 A NZ74817317 A NZ 74817317A NZ 748173 A NZ748173 A NZ 748173A
Authority
NZ
New Zealand
Prior art keywords
compound
formula
pharmaceutically acceptable
solid form
acceptable salt
Prior art date
Application number
NZ748173A
Other versions
NZ748173B2 (en
Inventor
Alexander Hird
Matthew Belmonte
Wenzhan Yang
John Secrist
Daniel Robbins
Steven Kazmirski
Dedong Wu
Bo Peng
Jeffrey Johannes
Michelle Lamb
Qing Ye
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NZ748173A publication Critical patent/NZ748173A/en
Publication of NZ748173B2 publication Critical patent/NZ748173B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia- 5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

Claims (15)

Claims
1. A compound which is 17-chloro-5,13,14,22-tetramethyloxa-2,9-dithia- 4,7 11,15 16,21 20,24 30,35 5,6,12,13,22-pentaazaheptacyclo[27.7.1.1 .0 .0 .0 .0 ]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaenecarboxylic acid (Formula I) or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein the compound is Formula I.
3. The compound of claim 1, wherein the compound is a pharmaceutically acceptable salt of the compound of Formula I.
4. The compound of claim 1, wherein the compound of Formula I has the structure of (R )chloro-5,13,14,22-tetramethyloxa-2,9-dithia-5,6,12,13,22- 4,7 11,15 16,21 20,24 30,35 pentaazaheptacyclo[27.7.1.1 .0 .0 .0 .0 ]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaenecarboxylic acid (Formula II) or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4, wherein the compound is Formula II.
6. The compound of claim 4, wherein the compound is a pharmaceutically acceptable salt of Formula II.
7. The compound of claim 1, wherein the compound of Formula I has the structure of (S )chloro-5,13,14,22-tetramethyloxa-2,9-dithia-5,6,12,13,22- 4,7 11,15 16,21 20,24 30,35 pentaazaheptacyclo[27.7.1.1 .0 .0 .0 .0 ]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaenecarboxylic acid (Formula III) (III) or a pharmaceutically acceptable salt thereof.
8. The compound of claim 7, wherein the compound is Formula III.
9. The compound of claim 7, wherein the compound is a pharmaceutically acceptable salt of Formula III.
10. The compound, or pharmaceutically acceptable salt thereof, of any one of claims 1-9, in crystalline form.
11. The compound of claim 4, wherein the compound is a solid form of Formula II.
12. The solid form of claim 11, wherein the solid form is Form A (R )chloro- 5,13,14,22-tetramethyloxa-2,9-dithia-5,6,12,13,22- 4,7 11,15 16,21 20,24 30,35 pentaazaheptacyclo[27.7.1.1 .0 .0 .0 .0 ]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaenecarboxylic acid monohydrate.
13. The solid form of claim 12, wherein the solid form has an XRPD pattern comprising at least one peak expressed as 2? (±0.2º) selected from about 7.0°, 8.4° and 12.5°.
14. The solid form of claim 12, wherein the solid form has an XRPD pattern comprising at least one peak expressed as 2? (±0.2º) selected from about 5.4°, 7.0°, 8.4°, 10.7°, 12.5°, 13.1°, 14.4°, 15.1°, 15.6°, 17.1° and 18.2°.
15. The solid form of claim 12, wherein the solid form has an XRPD pattern substantially similar to
NZ748173A 2017-04-21 Macrocyclic mcl1 inhibitors for treating cancer NZ748173B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662326156P 2016-04-22 2016-04-22
PCT/EP2017/059511 WO2017182625A1 (en) 2016-04-22 2017-04-21 Macrocyclic mcl1 inhibitors for treating cancer

Publications (2)

Publication Number Publication Date
NZ748173A true NZ748173A (en) 2025-05-02
NZ748173B2 NZ748173B2 (en) 2025-08-05

Family

ID=

Also Published As

Publication number Publication date
ME03729B (en) 2021-01-20
NI201800093A (en) 2019-03-14
US9840518B2 (en) 2017-12-12
DOP2018000222A (en) 2018-10-31
EP3445767A1 (en) 2019-02-27
SG11201805838UA (en) 2018-11-29
LT3445767T (en) 2020-05-25
EA036551B1 (en) 2020-11-23
CY1123186T1 (en) 2021-10-29
US11472816B2 (en) 2022-10-18
MA44721B1 (en) 2020-05-29
CO2018008759A2 (en) 2018-09-20
TN2018000319A1 (en) 2020-01-16
US20170305926A1 (en) 2017-10-26
CL2018002410A1 (en) 2018-12-07
HRP20200673T1 (en) 2020-07-10
HUE049591T2 (en) 2020-09-28
TWI742074B (en) 2021-10-11
CA3020378A1 (en) 2017-10-26
CR20180499A (en) 2019-01-25
AR108301A1 (en) 2018-08-08
JP6894449B2 (en) 2021-06-30
IL262237B (en) 2021-08-31
CN109071566A (en) 2018-12-21
MX386103B (en) 2025-03-18
ZA201807766B (en) 2021-09-29
MX2018012711A (en) 2019-05-30
EP3445767B1 (en) 2020-02-19
US20190185485A1 (en) 2019-06-20
KR102388208B1 (en) 2022-04-18
ES2791319T3 (en) 2020-11-03
BR112018070677A2 (en) 2019-02-05
US20180155362A1 (en) 2018-06-07
KR20180135030A (en) 2018-12-19
SV2018005742A (en) 2019-03-25
WO2017182625A1 (en) 2017-10-26
IL262237A (en) 2018-11-29
BR112018070677B1 (en) 2024-02-06
US20210230184A1 (en) 2021-07-29
US10196404B2 (en) 2019-02-05
PT3445767T (en) 2020-05-13
AU2017252222A1 (en) 2018-11-29
EA201892300A1 (en) 2019-05-31
PH12018502227A1 (en) 2019-07-29
MA44721A (en) 2019-02-27
US10889594B2 (en) 2021-01-12
CN109071566B (en) 2021-08-31
JP2019514863A (en) 2019-06-06
DK3445767T3 (en) 2020-05-18
RS60257B1 (en) 2020-06-30
PE20181803A1 (en) 2018-11-19
SI3445767T1 (en) 2020-07-31
TW201803879A (en) 2018-02-01
AU2017252222B2 (en) 2019-11-07
PL3445767T3 (en) 2020-07-13
SMT202000249T1 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
AU2015221439B2 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
EP4541422A3 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2024000299A (en) Anti-viral compounds.
EP4365179A3 (en) Novel rapamycin derivatives
PH12018500360A1 (en) Heteroaryl derivatives as parp inhibitors
WO2017123884A8 (en) Heterocyclic compounds as rsv inhibitors
MX2022015207A (en) Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections.
TN2016000090A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors.
MX2019004951A (en) PROCESS FOR THE PREPARATION OF PIRAZOLO [1,5-A] PYRIMIDINES AND SALTS OF THESE.
WO2014172188A3 (en) 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
WO2012030685A3 (en) Indazole derivatives useful as erk inhibitors
MY197116A (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2008142720A3 (en) Quinazolin-oxime derivatives as hsp90 inhibitors
MX2012009186A (en) Substituted pyrrolidine-2-carboxamides.
MX2016016538A (en) Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors.
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
MX2018008095A (en) Fused tricyclic heterocyclic compounds as hiv integrase inhibitors.
UA89123C2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MX2020011317A (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors.
WO2018209363A3 (en) Propionic acid derivatives and methods of use thereof
PH12021552513A1 (en) Pyrrole compounds
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
WO2018035346A8 (en) Kinase inhibitor compounds, compositions, and methods of treating cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 APR 2027 BY ANAQUA SERVICES

Effective date: 20260320